Mode
Text Size
Log in / Sign up

Butyrate and fecal acetate levels are significantly lower in patients with type 2 diabetesShort Chain Fatty Acids Linked to Type 2 Diabetes Levels

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that lower butyrate and fecal acetate levels are associated with type 2 diabetes compared to normal glucose tolerance.

This meta-analysis evaluated the association between short-chain fatty acids (SCFAs) and glycemic status in 7,371 participants. The study specifically examined butyrate, valerate, propionate, and acetate across different stages of glucose intolerance, including normal glucose tolerance (NGT), prediabetes, and type 2 diabetes (T2DM).

Key findings indicate that butyrate levels were significantly lower in T2DM compared to NGT (SMD: -0.49; 95% CI [-0.96, -0.01]). Additionally, fecal acetate and butyrate were significantly lower in the T2DM group compared to the NGT group. While valerate appeared higher in T2DM, this finding was not robust in sensitivity analysis. Acetate levels were lower in T2DM compared to pre-diabetes, though the authors noted that acetate patterns were less consistent across different glycemic comparisons and biological matrices.

The authors note several limitations, including inconsistent evidence regarding the association of certain SCFAs with T2DM and the lack of robustness in valerate data. These findings suggest that SCFAs serve as metabolic correlates of T2DM, though the observational nature of the included studies means these results indicate associations rather than direct causality.

How this fits prior evidence

This meta-analysis identifies specific short-chain fatty acids as metabolic correlates of type 2 diabetes. While not directly addressing the clinical management of complications like sarcopenia or the pharmacological effects of SGLT2 inhibitors or zinc supplementation mentioned in prior coverage, it provides a biochemical profile of the T2DM metabolic environment.

A large review of data from over 7,000 people looked at how short-chain fatty acids (SCFAs) relate to blood sugar health. These fatty acids, including butyrate, valerate, propionate, and acetate, are produced in the gut and are important for metabolism. The study compared people with normal glucose levels, those with prediabetes, and those with type 2 diabetes.

The researchers found that people with type 2 diabetes had significantly lower levels of butyrate and fecal butyrate compared to those with normal glucose. They also found lower levels of acetate in people with type 2 diabetes compared to those with prediabetes. While some other changes were noted, the evidence for some fatty acids was not consistent or strong enough to be certain.

Because this was a review of observational data, it shows a link between these fatty acids and diabetes, but it does not prove that one causes the other. The results for some fatty acids were inconsistent across different tests. These findings suggest that these gut acids are important markers for metabolic health, but more research is needed to understand their exact role.

What this means for you:
Lower levels of certain gut fatty acids are linked to type 2 diabetes, but more research is needed to confirm why.

Common questions

What are short-chain fatty acids?

Short-chain fatty acids (SCFAs) are molecules like butyrate, valerate, propionate, and acetate. They are produced in the gut and are important for metabolism. This study looked at how the levels of these specific acids change in people with normal glucose, prediabetes, and type 2 diabetes.

What did the study find about butyrate and diabetes?

The study found that butyrate levels were significantly lower in people with type 2 diabetes compared to those with normal glucose levels. This included both butyrate in the body and butyrate found in stool samples. These findings suggest butyrate is a key marker for metabolic health.

Are these findings a proven treatment for diabetes?

No, this study only shows a link between fatty acid levels and diabetes. Because it was a meta-analysis of observational data, it does not prove that changing these levels will treat the condition. You should speak with your doctor about any changes to your medical care.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Short-chain fatty acids (SCFAs) modulate insulin sensitivity, but evidence on their association with type 2 diabetes mellitus (T2DM) is inconsistent, possibly due to dynamic changes across the glycemic spectrum from normal glucose tolerance (NGT) to established T2DM. This systematic review characterizes stage-specific variation in SCFAs to assess their potential value as metabolic correlates of T2DM. PubMed, Web of Science, Embase, and the Cochrane Library were searched up to December 2025 for observational studies on SCFAs involving participants with NGT, prediabetes (pre-DM), or established T2DM. Continuous/binary outcomes were expressed as standardized mean differences (SMDs)/odds ratios (ORs) with 95% confidence intervals (CIs). Newcastle-Ottawa Scale (NOS) and Agency for Healthcare Research and Quality (AHRQ) criteria assessed study quality. Data were pooled using fixed-effects or random-effects models according to I2 heterogeneity. Subgroup analyses, sensitivity analyses, and funnel plots were performed. 17 studies (7,371 participants) were included. Based on 6 studies, butyrate was significantly lower in T2DM than in NGT (SMD: −0.49, 95% CI [−0.96, −0.01]), and the finding was robust in sensitivity analyses, whereas the observed increase in valerate was not. No significant differences in SCFAs were found between pre-DM and NGT except for propionate (1 study). Single-study analyses using either SMD or OR indicated lower acetate levels in T2DM than in pre-DM. Fecal, but not circulating, acetate and butyrate were significantly lower in T2DM than in NGT, with a significant sample-type subgroup difference only for acetate. SCFA alterations were more evident in established T2DM than in pre-DM, with reduced butyrate emerging as the most consistent finding. Acetate showed a less consistent pattern, varying across glycemic comparisons and biological matrices. These findings highlight SCFAs as key metabolic correlates of T2DM and support further prospective and interventional research on their potential nutritional and metabolic relevance. https://www.crd.york.ac.uk/prospero/. The Systematic Review Registration PROSPERO (No. CRD420251245821).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.